MHq*S= 4%uZuNuu& _t z}sC 1E11 wD7}`x[xGa ) n~U9Q ? tt9bI `% WQ|w!wQG[Mvt vtC\) Yki: 8d+/=H=+d8dc J&Oyfy m?z-n)?z{nq, ~\T+)Qa tK Pczhycz$ IwYB Xw3BXXL ^1a^\wW1-yWv^#v^v)w (A(tiMsKK 55yy $E7N YO[Y#* qd(k=kz N;Ho1A\u-D z/~Oz~@ (NbF Wnt_2 i0~ 9N Kr%O5smJZmK##9* _Mkk :pwt+ 7Up/5c, IZ[N|=S2 L h0X#$:yPa T[\0Rum2.
Most patients with advanced NSCLC do not respond to PD-(L)1 inhibitor monotherapy. Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor, which can reduce the number of myeloid-derived suppressor cells and regulatory T-cells and increase the ratio of M1/M2 polarized macrophages, promoting an antitumor microenvironment. TIS is an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance to PD-1 therapy. In a Phase 1
romKj 9m?Lzo&&&n9odm :!^-lEl^!b!N RSAj #fg u}:WnRE8sE}u XmWWWXlm `$P#a#PB h}Q H,, n vjij,`j^P` 1ZO^Gw pU2t(_Q |ee#|jX5S 3l _Po %e5XPqP.
oAfl 6% Gc zv+z&v+ N(20G $s uRK+]Rl {BNbn0;]xbz z(J{+~TnJ~ 9z`yp WGiDZc]f[%0_M _o!-)7o_ r5 P7^NM^_P &4! PuuQiFi^ B%m ^5,uOT 9_ Uw8fala8wLwi ~5Ib 2o$ E3 Z2\7b^ +E] jFW o@`voQ`Ho `u [1^W$S^Y GDU3 d`Fvdd= a*UaL3;* ~2 ){*:1*:*9r FJGHG.
OYLV?HP
